Perkins Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-6,625
| Closed | -$25K | – | 100 |
|
|
2023
Q1 | $25K | Buy |
6,625
+1,675
| +34% | +$6.32K | 0.02% | 93 |
|
|
2022
Q4 | $19K | Buy |
4,950
+50
| +1% | +$192 | 0.02% | 98 |
|
|
2022
Q3 | $39K | Buy |
4,900
+825
| +20% | +$6.57K | 0.04% | 96 |
|
|
2022
Q2 | $86K | Buy |
4,075
+750
| +23% | +$15.8K | 0.09% | 94 |
|
|
2022
Q1 | $125K | Buy |
3,325
+1,825
| +122% | +$68.6K | 0.1% | 96 |
|
|
2021
Q4 | $84K | Buy |
1,500
+450
| +43% | +$25.2K | 0.06% | 100 |
|
|
2021
Q3 | $76K | Buy |
1,050
+310
| +42% | +$22.4K | 0.05% | 99 |
|
|
2021
Q2 | $71K | Buy |
+740
| New | +$71K | 0.04% | 101 |
|